Sign in

    Scott A. Smith

    Chief Executive Officer (CEO) at Viatris Inc
    Board
    Since April 1, 2023
    Age
    62 years
    Tenure
    Joined the board in December 2022 and assumed the CEO role at Viatris on April 1, 2023, leading the company’s Phase 2 strategic plan for renewed growth and leadership.

    Also at Viatris Inc

    DCLG
    Dr. Corinne Le Goff
    Chief Commercial Officer (CCO)
    TM
    Theodora Mistras
    Chief Financial Officer (CFO)

    About

    Scott A. Smith, born in 1961, is a seasoned healthcare executive with over 35 years of experience in the pharmaceutical and biotechnology industries. His extensive career includes leadership roles at major companies such as Celgene Corporation, where he contributed to the commercial success of blockbuster drugs, and BioAtla, Inc., where he advanced clinical development and strategic business initiatives.

    At Viatris, he transitioned from a board member in December 2022 to Chief Executive Officer on 04-01-2023, where he now drives the company’s strategic evolution and operational excellence as part of its Phase 2 growth plan. His role is marked by his proven ability to oversee complex organizations and execute transformational strategies in the healthcare sector.

    Throughout his career, his leadership has been defined by a focus on innovation, strategic growth, and strong governance. Recognized for his contributions to global clinical development and commercial operations, he continues to shape the direction of Viatris while drawing on decades of industry expertise to build a resilient and forward-looking organization.

    $VTRS Performance Under Scott A. Smith

    Past Roles

    OrganizationRoleDate RangeDetails
    BioAtla, Inc. (NASDAQ: BCAB) President2018-2023Built a clinical development structure that advanced multiple assets from investigational new drug applications into late‑stage clinical development and led long‑term strategic operational and business development activities
    Celgene Corporation Senior Vice President, Global Head of Immunology; President of Inflammation and Immunology; President and Chief Operating Officer2008-2018 (COO from 2017)Held multiple executive roles leading oncology, inflammation, and immunology franchises, along with commercial operations and clinical development

    External Roles

    OrganizationRoleDate RangeDetails
    BioAtla, Inc. (NASDAQ: BCAB) DirectorN/AGlobal biotechnology company focused on Conditionally Active Biologics™ antibody therapeutics